UK: Amendments To UK Human Medicines Regulations 2012

Last Updated: 24 January 2019
Article by Adela Williams and Silvia Valverde

On 18 January, a new statutory instrument, the Human Medicines (Amendment) Regulations 2019 (the Amending Regulations), which amend the Human Medicines Regulations 2012, was laid before Parliament. These regulations will come into force on 9 February 2019.

The principal purpose of the amendments is to transpose into UK legislation the remaining provisions of Directive 2011/62/EU (the Falsified Medicines Directive), which require two new safety features to appear on the packaging of certain medicinal products, and the associated Commission Delegated Regulation 2016/161/EU (the Delegated Regulation), which sets out the details of these features. However, the Amending Regulations have also introduced an important new provision allowing for "serious shortage protocols" (SSPs) to be put in place for prescription-only medicines (POMs) in certain circumstances, and have extended the types of product containing naloxone (indicated for the treatment of opioid overdose) that drug treatment services may supply in an emergency.

Implementation of the Falsified Medicines Directive

The Falsified Medicines Directive introduces harmonised measures to prevent the entry of falsified, or counterfeit, medicines into the legal supply chain. Most of its provisions were transposed into UK legislation in 2013.

The Amending Regulations implement the remaining parts of the Falsified Medicines Directive, which require two new safety features, that enables the verification and identification of the product in question, to appear on the packaging of almost all POMs for sale in the European Economic Area: (i) a unique identifier contained in a 2D bar code; and (ii) an anti-tampering device. Wholesalers (including manufacturers conducting wholesale distribution activities) are required to scan the 2D barcode at various points in the supply chain to verify the authenticity of the medicinal product.

From 9 February 2019, medicines manufacturers will be required to place the safety measures on the packaging of certain medicines and upload information into a European data repository, as we discussed in a previous post.

The general rule is that persons authorised to supply medicinal products to the public shall verify the safety features at the time of such supply, and decommission the unique identifier. The Amending Regulations, however, adopt the optional provisions at Article 23 of the Delegated Regulation, which require wholesalers to verify and decommission the unique identifier at the time of supply to certain categories of persons (who are therefore relieved of the verification and decommissioning obligation) including: persons who are authorised or entitled to supply medicinal products to the public but do not operate within a healthcare institution or pharmacy; dentists; registered optometrists and registered dispensing opticians; registered paramedics; members of the armed forces; police forces, government institutions maintaining stocks of medicinal products for the purpose of civil protection or disaster control; universities or other higher education or research institutions; prison services; persons carrying on the business of a school; care homes; and hospices.

The Amending Regulations create various offences relating to breaches of the new requirements in the UK, including the detailed provisions of the Delegated Regulation by marketing authorisation holders, parallel distributors, persons authorised to supply medicinal products to the public, and legal entities managing repositories where information on the safety features is contained, and establishes powers of inspection, sampling and seizure.

Serious Shortage Protocol

The current provisions of the Human Medicines Regulations 2012 require the sale or supply of POMs only in accordance with a prescription given by an appropriate practitioner (i.e. a doctor, dentist, supplementary prescriber or a nurse or pharmacist independent prescriber). The Amending Regulations make provision, via new regulation 226A, for a serious shortage protocol (SSP) to be issued by the Ministers where there is or may be a serious shortage of a POM. This written protocol would enable pharmacists to sell or supply against the protocol rather than a prescription. The new provisions have been prompted principally, although not exclusively, by the risk of medicines shortages in the event of a "no deal" Brexit.

Currently, if a pharmacist is unable to dispense the POM as prescribed, he or she may not dispense an alternative unless the prescription is or will be revised by the prescriber. The purpose of the amendment is that, in the event of a serious shortage of a POM that affects or may affect the whole or any part of the UK, an SSP may be issued by Ministers which allows pharmacists to dispense a different quantity, pharmaceutical form or strength of the POM to that prescribed, or a different POM (a generic equivalent, a similar biological medicinal product or a therapeutic equivalent) as specified in the SSP without reverting to the prescriber for revision of the prescription. The SSP should specify the period for which and the parts of the UK in which the protocol is to have effect.

The Department of Health stated, in its response to consultation on the proposal to introduce SSPs, that these would be used only in exceptional circumstances if they would assist in managing the supply situation, and if clinicians consider them appropriate, after discussion with the manufacturer and/or marketing authorisation holder. Protocols for therapeutic or generic equivalents will not be suitable for all medicines and patients. For example, the Department of Health states that those types of SSP would not be suitable for treatments for epilepsy or treatments requiring biological products where the medicines that are prescribed need to be prescribed by brand for clinical reasons. In these cases, patients would always be referred to the prescriber for any decision about their treatment, before a therapeutic or generic alternative is supplied.

Ministers are required to review the operation of the new regulation 226A, in particular whether it has resulted in any adverse consequences for the market in POMs or for patient safety, and to publish a report as soon as is reasonably practical after the end of one year, beginning on the day on which the first SSP is issued.

Availability of Naloxone

Finally, the new Amending Regulations provide for drug treatment services to obtain and supply all preparations of naloxone, not limited to the injectable preparation that is already listed in the current text of the Human Medicines Regulations 2012. Public Health England will work with the Department of Health and Social Care and the MHRA to publish advice supplementary to existing guidance.


The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions